Aro Biotherapeutics Announces $88M Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines
Executive Summary
Aro Biotherapeutics Co. (developing tissue-targeted genetic medicines) announced the closing of an $88M Series A financing. Northpond Ventures and Cowen Healthcare Investments led the round, with participation from HealthCap, BVF Partners, and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, BioMotiv, and Ionis Pharmaceuticals also participated in the round. Aro is developing a unique class of Centyrin-conjugated RNA therapies to efficiently and selectively target RNA medicines to the specific site of disease. The proceeds from the Series A will be used to advance the company’s lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice